Veralox Therapeutics is developing small molecule therapeutics that inhibit the 12-Lipoxygenase pathway to treat Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). By targeting this enzyme, the company aims to reduce proinflammatory metabolites that contribute to platelet activation in HIT and enhance insulin production in T1D.

Vitestro develops an autonomous blood drawing device that utilizes AI-based, ultrasound-guided imaging and robotic needle insertion to automate the entire blood collection process. This technology addresses the shortage of healthcare personnel by increasing the efficiency and availability of blood drawing services in hospitals, allowing patients to receive timely diagnostics on their own schedule.